The global structural heart devices market size is expected to reach USD 12.8 billion by 2030, registering a CAGR of 9.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness exponential growth over the next 8 years due to the rapid increase in cardiovascular conditions and increasing power of healthcare expenditure.
The defects are mostly present at birth, thereby directly affecting the under-5 mortality rate of a country. Therefore, rigorous actions are being undertaken by various government bodies across the globe to increase access to treatment. The Centers for Disease Control and Prevention have a public action plan for efficient management of cardiac conditions.
In addition, other organizations are working on improving the scenario for structural heart disease treatment. For instance, in November 2016, the Cardiovascular Research Foundation (CRF) announced a launch of a journal focusing on the diagnosis and treatment of structural heart defects. It was titled Structural Heart: The Journal of the Heart Team and is expected to be launched in May 2017. This is expected to trigger research & development activities along with capital invested in this field, resulting in technological advancements.
Request a free sample copy or view report summary: Structural Heart Devices Market Report
Surgical Aortic Valve Replacement (SAVR) dominated the market in 2022, closely followed by Transcatheter Aortic Valve Replacement (TAVR). It can be attributed to the longest presence of the technique in the treatment regimen of aortic stenosis
Left Atrial Appendage Closure (LAAC) is anticipated to be one of the fastest-growing segment owing to the minimally invasive nature of the procedure. It also helps in the reduction of risk of stroke, thus is projected to have a higher demand
Geographically, North America held the largest structural heart devices market share in 2016 and is expected to maintain its position during the forecast period. A high prevalence of cognitive heart diseases is the key reason for this dominance. Moreover, the mandatory CCHD screening for newborns imposed by the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) in September 2014 also contributes to the growth in this region
Asia Pacific is also expected to witness rapid growth over the forecast period. The improved access and capability for treatments in this region is the key reason for this growth
Grand View Research has segmented the structural heart devices market based on type and region:
Structural Heart Devices Type Outlook (Revenue, USD Million, 2018 - 2030)
SAVR (Surgical Aortic Valve Replacement)
TAVR (Transcatheter Aortic Valve Replacement)
Mitral Repair (Annuloplasty)
LAAC (Left Atrial Appendage Closure)
Structural Heart Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
China
Japan
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Kuwait
List Of Key Players Structural Heart Devices Market
Boston Scientific Corporation
Medtronic
Edwards Lifesciences Corporation
Abbott Laboratories
ST. JUDE MEDICAL
Biomerics
Comed BV
LivaNova PLC
JenaValve Technology, Inc.
CardioKinetix
"The quality of research they have done for us has been excellent..."